Loading…
The acquisition is expected to close in the fourth quarter of 2025.
Roche has entered into a definitive merger agreement to acquire 89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases. The acquisition is expected to close in the fourth quarter of 2025.
Under the terms of the agreement, 89bio shareholders will receive US$14.50 per share in cash at closing, and up to an aggregate of US$6.00 per share in cash, resulting in a total equity value of approximately US$2.4 billion. The total deal value could reach up to approximately US$3.5 billion.
As of the latest data, 89bio, Inc. has a free float of 97,041,000 shares and 148,492,000 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.